Axon Therapies, Inc.

Axon Therapies, Inc. specializes in innovative medical solutions targeting heart failure patients, specifically those with preserved ejection fraction (HFpEF), through advanced catheter technology. Founded in 2016 in New York, US, Axon Therapies, Inc. focuses on developing solutions for heart failure management.

The company's leadership includes Zoar Engelman as the founder and Chad Hoskins as the CEO. In September 2025, Axon Therapies, Inc. raised USD 32 million in series A funding co-led by new investors Earlybird Venture Capital and Sante Ventures, with participation from other new investors CD Capital and KOFA Healthcare Investments. Returning investor Deerfield Management also participated in the round.

Axon Therapies focuses on innovative medical solutions for patients suffering from heart failure, particularly those with preserved ejection fraction (HFpEF). Their primary product, the Axon Ablation Catheter, offers a novel implant-free procedure that targets the right greater splanchnic nerve through the femoral vein. The device utilizes targeted ablation therapy to interrupt nerve signals, thereby reducing sympathetic activity and aiding in the normalization of fluid balance within the body. The procedure is designed to be minimally invasive, typically completed in under an hour, and is intended for outpatient settings.

Axon Therapies primarily targets healthcare providers, cardiologists, and hospitals in the United States, with an eye on expanding into additional markets that are currently addressing the high unmet need in heart failure management. The revenue model for Axon Therapies is centered around partnerships with healthcare facilities and cardiologists who adopt their flagship product, the Axon Ablation Catheter. These transactions occur directly between Axon Therapies and medical institutions, where the catheter is procured for use in outpatient procedures. The company potentially engages in B2B transactions, providing training and support services to ensure proper use of the device.

Pricing structures for their products are designed to reflect the novel nature and effectiveness of the treatment, which emphasizes patient outcomes and procedural efficiency. As a result, revenue is generated through the sale of the ablation catheter and associated support services, establishing a sustainable business model within the cardiology sector. The company plans to utilize the September 2025 funding to advance clinical development, including two feasibility studies in heart failure, a widespread condition with limited treatment options.